Medication-related osteonecrosis of the jaw: prevention, recognition and dental management

Clinical scope and immediate priorities

Medication-related osteonecrosis of the jaw is uncommon but clinically important in patients exposed to potent antiresorptive or selected antiangiogenic therapy. Risk is substantially influenced by indication and cumulative exposure, with oncology-dose regimens carrying greater risk than routine osteoporosis therapy. Fear of MRONJ should not lead to unplanned discontinuation of medicines that prevent major skeletal harm. Oral and dental presentations sit at the interface of local disease, systemic health and medication safety. Definitive dental treatment is often more important than repeated courses of symptomatic medication. Clinicians should recognise spreading infection, airway risk, cancer warning signs, bleeding risk and medication-related complications, while coordinating with medical teams when systemic disease changes procedural risk.

Recognition and differential diagnosis

Persistent exposed bone or bone that can be probed through a fistula in the maxillofacial region, without prior jaw radiation or metastatic disease explaining the lesion, is characteristic of established MRONJ. Pain, swelling, loosening teeth, altered sensation or non-healing extraction sites can precede overt exposure. Dental infection and trauma remain important competing diagnoses. The practical aim is to identify features that change urgency, distinguish common mimics and avoid anchoring on a single test result. Where the presentation is atypical, reassess the working diagnosis rather than forcing the findings to fit it.

Assessment and investigations

Record the exact drug, indication, route, dose schedule and duration, together with corticosteroids, smoking, diabetes and dental infection. Examine the entire mouth and use imaging according to symptoms and specialist advice. Before initiating high-dose oncology antiresorptive treatment, dental assessment and completion of necessary invasive care can reduce future risk when oncologically feasible. Investigations should be sequenced so that urgent bedside information is obtained first, followed by tests that refine cause, severity or treatment choice. Trends, prior results and treatment effects often matter more than whether one value sits just inside or outside a reference range.

Initial and definitive management

Prevention focuses on maintaining oral health and avoiding untreated infection. Established MRONJ management ranges from conservative oral hygiene, antiseptic measures and symptom control to surgical treatment, depending on symptoms, stage and specialist judgement. Drug holidays remain controversial and should not be initiated by the dental team without discussion of fracture or cancer consequences with the prescriber. Treatment should address reversible causes and immediate physiological risk while preserving options for definitive care. Medication selection requires attention to allergies, interactions, renal or hepatic function, pregnancy where relevant, and the possibility that a medicine suitable in one health system may not be first-line in another.

Escalation, complications and special situations

Progressive infection, pathological fracture, extraoral fistula, extensive necrosis or significant pain warrants oral/maxillofacial specialist management. Suspected malignancy or osteomyelitis should remain in the differential when clinical findings are atypical. Escalate early when instability, organ dysfunction, rapidly progressive symptoms or a high-risk comorbidity is present. Frailty, pregnancy, immunosuppression, extremes of age and major renal or hepatic impairment can alter both presentation and treatment tolerance, so protocol-based care still requires individualisation.

International practice across English-speaking health systems

Across the United Kingdom, United States, Canada, Australia, New Zealand and Ireland, the core clinical principles are broadly similar, but drug licensing, formularies, emergency pathways, screening thresholds, referral criteria and professional scope can differ. Use the most recent national or regional guidance, local antimicrobial or medicines policy, and the relevant product information when an operational detail could change treatment. MDPDA therefore presents a common evidence-based framework and highlights areas that should be adapted locally rather than implying that one country’s pathway is universal.

Monitoring, follow-up and prevention

Follow-up should be purposeful rather than routine. Define what is being monitored, when it should be reassessed and what finding would change management. Review adherence and adverse effects, repeat objective measurements when they inform risk, and reconsider the diagnosis if the clinical course is inconsistent with expectations. Safety-netting should state which symptoms require urgent reassessment and which service should be contacted. For chronic disease, prevention, vaccination where relevant, smoking cessation, nutrition, physical activity and management of related cardiovascular or metabolic risk can be as important as disease-specific treatment. Patients continuing relevant therapy need regular preventive dental care and prompt treatment of infection. Document shared decisions about invasive procedures and medication management, including the differing baseline risk between osteoporosis and oncology dosing.

Common pitfalls and safety checks

Do not stop antiresorptive therapy independently because dental extraction is planned. MRONJ risk with osteoporosis-dose therapy is not equivalent to high-dose oncology treatment. Untreated dental infection itself creates morbidity and may increase future procedural need. A non-healing jaw lesion requires a differential diagnosis, not automatic attribution to medication. A useful final check is to ask what dangerous alternative diagnosis could still explain the presentation, whether the patient has demonstrated an appropriate response to treatment, and whether the discharge or transfer plan is safe if symptoms recur.

Documentation, communication and shared decisions

Documentation should make the clinical reasoning visible. Record the key positive and negative findings, relevant risk stratification, important investigations, treatment rationale, discussions with the patient or family where appropriate, and the trigger for escalation or review. When care crosses settings, handover should identify unresolved diagnostic questions, medicines started or withheld, pending results and who is responsible for follow-up. Shared decisions are particularly important when more than one reasonable strategy exists or when treatment benefit must be balanced against bleeding, frailty, treatment burden or quality of life.

Implementation across care settings

Implementation requires coordination between dental and medical care when systemic disease or medicines alter procedural risk. Record the dental diagnosis, planned source control, analgesic or antimicrobial rationale and any advice obtained from the prescribing clinician. Where urgent dental access is limited, safety-net explicitly for spreading infection, airway symptoms, uncontrolled bleeding or suspected malignancy. Preventive care, fluoride exposure, periodontal maintenance and smoking cessation should be integrated into follow-up because repeated emergency treatment without prevention creates avoidable morbidity. National dental formularies and scope-of-practice rules should be followed for operational prescribing details.

Quality and patient-safety review

Before closing the episode of care, confirm that the working diagnosis remains consistent with the observed course, that high-risk alternatives have been considered, and that treatment has not introduced a new avoidable hazard. Review allergies, interactions, renal or hepatic constraints, pregnancy considerations where relevant, and the patient’s ability to follow the plan. The safest pathway is one in which the next clinician can understand what has been decided, what remains uncertain and which finding should trigger escalation.

Applying evidence to the individual patient

Guidelines provide a framework, but safe implementation depends on the patient’s baseline function, comorbidities, concurrent medicines, treatment goals and access to follow-up. Recommendations should be interpreted in light of absolute rather than relative benefit where possible, and clinicians should identify when the evidence base under-represents older people, pregnancy, severe kidney or liver impairment, multimorbidity or other groups. When two reasonable options exist, explain the trade-offs and document the reason for the selected approach. If local policy differs from an international recommendation, determine whether this reflects formulary, service configuration, licensing or genuinely different evidence. Reassessment is part of evidence-based care: a working diagnosis or treatment plan that no longer fits the clinical course should be revised rather than defended simply because it matched the initial pathway.

Practical review checklist

Before finalising management, confirm that the severity has been classified correctly, essential investigations have been acted on, and any test still pending has a named clinician or service responsible for review. Reconcile regular medicines and temporary changes, check whether monitoring is required after initiation or dose adjustment, and make the follow-up interval proportionate to risk. Explain the plan in language the patient can use, including what improvement is expected, which adverse effects matter and which symptoms require urgent help. Where care is shared between primary, secondary, dental, pharmacy or community services, avoid ambiguous instructions such as ‘follow up as needed’; specify who should do what and when. This final systems check often prevents harm that is not caused by the clinical decision itself but by gaps in implementation.